Lyell Immunopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYEL research report →
About the company
Lyell Immunopharma, Inc. , a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
- CEO
- Lynn Seely
- IPO
- 2021
- Employees
- 161
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $327.84M
- P/E
- -0.83
- P/S
- 10575.61
- P/B
- 1.12
- EV/EBITDA
- -1.20
- Div Yield
- 0.00%
- Gross Margin
- -7422.58%
- Op Margin
- -618909.68%
- Net Margin
- -794858.06%
- ROE
- -85.71%
- ROIC
- -59.39%
- Revenue
- $36.00K · -40.98%
- Net Income
- $-274,448,000 · 19.98%
- EPS
- $-16.06 · -1125.95%
- Op Income
- $-203,774,000
- FCF YoY
- 7.40%
- 52W High
- $45.00
- 52W Low
- $9.03
- 50D MA
- $16.52
- 200D MA
- $20.78
- Beta
- -0.09
- Avg Volume
- 137.94K
Get TickerSpark's AI analysis on LYEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Innovative Cellular Therapeutics Holdings Ltd | other | 76,000 |
| Jun 15, 26 | Innovative Cellular Therapeutics Holdings Ltd | other | 66,500 |
| May 18, 26 | Innovative Cellular Therapeutics Holdings Ltd | other | 0 |
| May 11, 26 | Seely Lynn | sell | 388 |
| May 11, 26 | Lee Gary K. | sell | 130 |
| May 11, 26 | Hill Stephen J. | sell | 89 |
| May 11, 26 | Bulis Veronica Sanchez | sell | 217 |
| Jun 10, 26 | RIEFLIN WILLIAM JL | other | 9,250 |
| Jun 10, 26 | Ramachandra Sumant | other | 9,250 |
| Jun 10, 26 | NABEL ELIZABETH G | other | 9,250 |
Our LYEL coverage
Recent articles, reports, and earnings notes.
No research on LYEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LYEL report →Similar companies
Peers in the same neighborhood.